Effects of carvedilol on renal function

Dupont, Alain

doi:10.1007/bf01409473

Cited by 33 publications

(11 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In particular, traditional β-blockers cause vasoconstriction as a result of decreased cardiac output, which may also decrease renal perfusion [43]. Long-term administration of carvedilol to patients with essential hypertension did not cause an impairment in renal function; carvedilol increased renal blood flow and decreased peripheral resistance [44][45][46]. A comprehensive review of the effects of β-blockers on renal function and their use in a patient with chronic kidney disease is discussed in a recently published paper by Bakris et al [47].…”

Section: Carvedilolmentioning

confidence: 99%

Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol

Fonarow¹

2006

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

Carvedilol is a third-generation beta(1)- and beta(2)-blocker that also possesses alpha(1)-adrenergic-blocking properties. This compound has: i) shown superior efficacy to certain other beta-blockers in heart failure, ii) can improve myocardial function (e.g., in myocardial infarction) and iii) is the only beta-blocker shown to significantly reduce mortality and morbidity (such as reinfarction and development of heart failure) in postmyocardial infarction patients with left ventricular dysfunction (LVD). The currently available preparation of carvedilol needs to be taken twice daily; however, studies have shown that the need for twice-daily dosing may decrease adherence. A once-daily formulation of carvedilol (controlled release) is expected to become available in 2007. The pharmacokinetic and pharmacodynamic properties of the new formulation are equivalent to the twice-daily formulation. A number of investigations have demonstrated equivalence between the twice-daily and once-daily formulations; thus, carvedilol controlled-release is expected to provide not only the same life-prolonging benefits of twice-daily carvedilol, but also the convenience of once-daily dosing.

show abstract

Section: Carvedilolmentioning

confidence: 99%

Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol

Fonarow¹

2006

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…20 Carvedilol as a new generation beta-blocker has no such effects on renal blood flow and GFR. 21 Added to this, many studies including our meta-analysis support superiority of carvedilol over beta-1 blockers as nephroprotective agent. [8][9][10][11][12][13] Achieving target level blood pressure is of high significance in patients with chronic renal failure.…”

Section: Discussionmentioning

confidence: 80%

Carvedilol as nephroprotective agent: a meta-analysis of randomized controlled trials

Hiremath

Lokikere

2016

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

“…When the renal hemodynamics were investigated in patients, a clear reduction of renal vascular resistance was demonstrated (54). An improvement of left ventricular diastolic function has also been described with carvedilol treatment both in hypertensives and in patients with ischemic heart disease (55).…”

Section: Hemodynamics In Hypertensionmentioning

confidence: 97%

Carvedilol in the Treatment of Hypertension - A Review of the Clinical Data Base

Hansson

Himmelmänn²

1998

Scandinavian Cardiovascular Journal

View full text Add to dashboard Cite

Scand Cardiovasc J Suppl 47: 67-80, 1998. Carvedilol is a novel antihypertensive agent. It is a multiple-action neurohormonal antagonist with a beta-adrenoceptor blocking effect combined with a vasodilating action based on alpha 1 -adrenoceptor blockade. In addition, carvedilol exerts a number of well documented ancillary effects such as being a scavenger of free radicals. It also has an antiproliferative action on smooth muscle cells. This combination of effects opens up a number of interesting clinical perspectives. It is the purpose of this brief review to summarize some of the clinical studies that have been performed with carvedilol. Investigations in hypertensive patients will form the basis of this review, but special interest will also be devoted to other patient groups. In particular the therapeutic value of carvedilol will be discussed in patients with concomitant disorders such as atheromatosis, left ventricular hypertrophy, angina pectoris, myocardial infarction, congestive heart failure, arrhythmias, stroke, renal failure or diabetes. Finally, the usefulness of carvedilol in the treatment of elderly hypertensive patients will be reviewed. It is evident from the available scientific literature that carvedilol is an antihypertensive agent with a novel mode of action. It is effective in many of the subpopulations of patients alluded to above. It appears reasonable to assume that some of these therapeutic effects can be attributed to its ancillary properties. Scand Cardiovasc J 32 REVIEW ARTICLE Scand Cardiovasc J Downloaded from informahealthcare.com by Nyu Medical Center on 06/17/15 For personal use only. 68 L. Hansson and A. Himmelmann Scand Cardiovasc J 32 Scand Cardiovasc J Downloaded from informahealthcare.com by Nyu Medical Center on 06/17/15 For personal use only. Scand Cardiovasc J 32 Scand Cardiovasc J Downloaded from informahealthcare.com by Nyu Medical Center on 06/17/15 For personal use only.

show abstract

Effects of carvedilol on renal function

Cited by 33 publications

References 25 publications

Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol

Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol

Carvedilol as nephroprotective agent: a meta-analysis of randomized controlled trials

Carvedilol in the Treatment of Hypertension - A Review of the Clinical Data Base

Contact Info

Product

Resources

About